Recent posts

Mass detection and mAb QC: How a cost-effective and robust peptide mapping method confirms CDR peptides – and can be validated

By March 15, 2016

The quality issues of biopharmaceutical therapeutics are definitely different from chemical drugs because of the increased complexity of manufacturing processes and complexity of the biologic molecules themselves. There is an increasing need for detailed product… Read more >

Categories: Pharmaceutical, Technologies
Tags: , , , , ,

Three Reasons for Biopharmaceutical Labs to Add Mass Detection to Routine Analyses

By March 9, 2016

As regulators focus in on the critical quality attributes of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations – other than to run more assays?

Categories: Pharmaceutical, Technologies
Tags: , , , , , , , , , , , , , , , , , , , ,

Multiple Attribute Monitoring of Biopharmaceuticals Using Mass Detection

By September 3, 2015

Multiple attribute monitoring has become a hot topic of discussion within biopharmaceutical organizations as the methodology allows detection and measurement of more critical quality attributes than conventional methods. Waters recently sponsored an outstanding webinar on… Read more >

Categories: Pharmaceutical, Technologies
Tags: , , ,